FindTrial
Sign In

Ultrasound, Immunology and Genomics for Understanding Therapy Response in Breast Cancer

Measuring the Response to Neo-Adjuvant Chemotherapy for Breast Cancer using Novel Ultrasound Device and Quantitative Multi-Omics Data - A pilot study - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/091416
Enrollment
68
Registered
2025-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Indian Institute of Technology Hyderabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Locally advanced breast cancer (TNM stage greater than or equal to T1c or patients satisfying the clinical criteria for neoadjuvant chemotherapy)

Exclusion criteria

Exclusion criteria: 1. Recurrent disease 2. Metastatic disease 3. Unable to tolerate chemotherapy

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study is the ability to understand the relationship between tumor morphology, immune infiltration, and genetic variations.Timepoint: These will be assessed at the baseline, 4 weeks post-neo-adjuvant chemotherapy, and 8 weeks post-neo-adjuvant chemotherapy.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Avinash Eranki

IIT Hyderabad

aeranki@bme.iith.ac.in04023016110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026